Welcome to Mesothelioma.net - Turning Hope and Faith into Action.

New Studies Confirm Effectiveness of Mesothelioma Treatment

When a team of scientists indicate that they have successfully killed mesothelioma cancer cells, the medical world sits up and takes notice. But when another team returns and announces that they’ve taken the study one step further and have garnered even greater results, it is big news.

That is exactly what is happening in the world of mesothelioma research today, as researchers from the Hyogo College of Medicine and the Hyogo University of Health Sciences have indicated that they have created a newly-synthesized analogue called HUHS1015 that has triggered not only apoptosis in mesothelioma cells, but also necrosis. The team is following on the heals of their earlier research into the effects of the popular blood pressure drug called naftopidil. Naftopidil is sold in the U.S. market under the name Flivas, and has been used beyond its original purpose to treat Raynaud’s disease and prostate conditions. The team’s earlier studies determined that the drug ups the presence of specific microRNAs that trigger mesothelioma cell death; now the compound that the team has created, which is chemically similar to naftopidil, goes beyond the benefits attributed to its predecessor.

The study’s results were published in the December 19th issue of Molecules, and according to author Tomoyuki Nishizaki, he and his colleagues found that laboratory mice inoculated with Stage IV mesothelioma cells as well as gastric cancer cells and colon cancer cells showed signs of suppressed tumor growth, as well as premature death. Interestingly, it appears that HUHS1015 acts in different ways in each of the different types of cancer cells, though in all cases it successfully kills the cells.

The team’s conclusions regarding the impact of HUHS1015 are that it holds the possibility of being a more effective protocol for the treatment of mesothelioma than many of the other, more commonly used cancer treatments that are currently in use. Remarkably, this includes the current gold standard treatment, cisplatin. Beside their feeling that it is more effective, they point out that it also has the advantage of subjecting patients to fewer uncomfortable side effects.

The group intends to continue to study the impacts of both naftopidil and the new analogue, with the hope that their efforts will move treatment of pleural mesothelioma further forward. Mesothelioma currently impacts approximately 3,500 victims in the United States every year, and generally results in death within a year or two of diagnosis.

Terri Oppenheimer

Terri Oppenheimer is an experienced blog writer, editor, and proofreader. She graduated from the College of William and Mary with a degree in English. She specializes in providing content for websites and finds tremendous enjoyment in the things she learns while doing her research. Her specific areas of expertise include health, medical research, and law.

Get Your FREE Resources Sent Overnight

  • New treatment options
  • Veterans benefits & claims
  • $30 Billion asbestos trust fund information

– Or Call –

Site Navigation

Where can I

Get Additional Help?

For over 15 years, we’ve provided the best FREE resources to mesothelioma patients and loved ones. Our resources include information on the leading treatment options and best doctors in your area; lessons learned from survivors; claims and benefits specifically for Veterans; and how to access your share of billions of dollars in trust fund money.

Get Your FREE Resources Sent Overnight

  • New Treatment Options
  • Veteran's Benefits & Claims
  • $30 Billion Asbestos Trust Fund Information

– Or Call –

We are here to help you


If you've been diagnosed with asbestos-related cancer, contact us at 1-800-692-8608 to find out if you are eligible to receive compensation. You can also fill out the form above to receive FREE information.

Quick Compensation - $30 Billion Trusts
$30 Billion Asbestos Trusts
Get Started